How to Validate Predictive Immunohistochemistry Testing in Pathology?: A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer

scientific article published on 11 October 2018

How to Validate Predictive Immunohistochemistry Testing in Pathology?: A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer is …
instance of (P31):
editorialQ871232
scholarly articleQ13442814

External links are
P356DOI10.5858/ARPA.2018-0410-ED
P698PubMed publication ID30307747

P2093author name stringErik Thunnissen
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectpathologyQ7208
immunohistochemistryQ899285
heterogeneityQ928498
non-small-cell lung carcinomaQ3658562
P304page(s)11-12
P577publication date2018-10-11
P1433published inArchives of Pathology & Laboratory MedicineQ4787305
P1476titleHow to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer
P478volume143

Reverse relations

cites work (P2860)
Q92980076Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis
Q92066104External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different

Search more.